Wei, Xiao X. http://orcid.org/0000-0001-7093-0383
Kwak, Lucia
Hamid, Anis
He, Monica
Sweeney, Christopher http://orcid.org/0000-0002-0398-6018
Flanders, Scott C.
Harmon, Matthew
Choudhury, Atish D. http://orcid.org/0000-0001-9344-6631
Article History
Received: 24 June 2021
Revised: 14 November 2021
Accepted: 12 January 2022
First Online: 10 February 2022
Competing interests
: There are no disclosures for work conducted at Dana-Farber Cancer Institute. AH: Consulting or Advisory Role: Merck Sharp & Dohme ADC: Advisory Role: Clovis, Dendreon, Bayer and Eli Lilly. CS: Consulting or Advisory Role: Sanofi, Janssen, Astellas Pharma, Bayer, Genentech, Pfizer, Lilly, Research Funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer (Inst), Sotio (Inst), Dendreon (Inst); Patents, Royalties, Other Intellectual Property: Pathenolide (Indiana University): dimethylaminoparthenolide (Leuchemix); Exelixis: Abiraterone plus cabozantinib combination. Stock or Other Ownership: Leuchemix. MH: Currently employee of Dendreon. SCF: Former employee of Dendreon. XW: Advisory Role: Novartis; Research funding: Bristol Myers Squibb (Inst).